Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.DARE · Entity 7799 | Chief Accounting Officer | January 30, 2026 | February 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date January 30, 2026 · Filed February 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-01-30 | Direct | 49,000 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 49,000 · Balance 49,000 F1: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 2, 2026 21:05 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001535596-26-000002 · wk-form4_1770066346.xml · derivative · entry 1 Haring-Layton MarDee · CIK 0001535596 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 Underlying: Common stock · 49,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| September 04, 2025 Filed Sep 4, 2025 21:59 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001401914-25-000046 · wk-form4_1757023159.xml · derivative · entry 1 Haring-Layton MarDee · CIK 0001535596 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common stock · 57,000 shares Expires 2035-09-04 F1 · derivative.exercise_date: This stock option was granted to the reporting person as a retention award and vests and becomes exercisable on 9/4/2027, provided, that, if certain performance criteria are satisfied, it will vest and become exercisable on the date such performance criteria are satisfied, subject to the reporting person's continuous service to the issuer. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 22:34 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001401914-25-000006 · wk-form4_1738362847.xml · derivative · entry 1 Haring-Layton MarDee · CIK 0001535596 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common stock · 38,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:28 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 290,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001401914-24-000004 · wk-form4_1710448076.xml · derivative · entry 1 Haring-Layton MarDee · CIK 0001535596 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,000 Underlying: Common stock · 290,000 shares Expires 2034-03-12 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.